JW Therapeutics’ IND is cleared by China NMPA for CAR T-Cell therapy in large B-Cell lymphoma

Share This Post

China’s National Medical Products Administration (NMPA) has approved JW Therapeutics’ investigational new drug (IND) application for a key clinical trial of Carteyva (relmacabtagene autoleucel) in people with second-line large B-cell lymphoma. The trial started in April 2022.

Carteyva is an autologous anti-CD19 CAR T-cell immunotherapy for relapsed or refractory large B-cell lymphoma that has previously been authorised in China. Patients who have not achieved a complete response (or have relapsed within 12 months) on first-line therapies such as anthracyclines, Genentech/Rituxan Biogen’s (rituximab), or other CD20-targeting agents will be enrolled in the new Phase III trial, which will compare Carteyva to standard second-line therapy.

Prior to starting this study, JW completed the Phase II RELIANCE trial, which saw a 75.9% overall response rate to Carteyva and a 51.7 percent complete response rate. With a median follow-up time of 17.9 months, overall survival was 76.8%. Carteyva was approved by Chinese regulators in 2021 for relapsed or refractory large B-cell lymphoma based on this research.

Large B-cell lymphomas are the most prevalent subtype of B-cell lymphomas, which account for 85 percent of non-Hodgkin lymphomas. The conventional first-line treatment is rituxan plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, R-CHOP does not cure 30 to 50 percent of patients, who either relapse or become chemo-resistant. Salvage immunotherapy followed by high-dose chemotherapy and stem cell transplantation has been the traditional second-line therapy for large B-cell lymphoma for decades, but it only works approximately a quarter of the time.

Juno Therapeutics’ orvacabtagene autoleucel was generated from the same CAR design as Carteyva. Juno, a Bristol Myers Squibb company, and Shanghai-based WuXi AppTec partnered to become JW in 2016.

JW is working on CAR T-cell treatments for multiple myeloma and follicular lymphoma, in addition to large B-cell lymphoma. JW’s IND to examine their BCMA-targeted CAR T-cell treatment JWCAR129 in relapsed or refractory multiple myeloma was approved by the NMPA last year. JW’s new medication application for Carteyva in relapsed or refractory follicular lymphoma was accepted by the FDA in early March.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy